There is a **compelling need** for expanding vaccine-manufacturing capacity and capabilities across the African continent - the target defined by the PAVM is a **strong rallying cry** to initiate change.

The African vaccine-manufacturing industry today is still in its very early stages but is **not starting from zero**, with a dozen African players spread across the continent.

The PAVM FFA has put forward **one vision of the African vaccine-manufacturing ecosystem** based on its analysis and 2040 goals.

**Many promising announcements** have been made and initiatives have been launched in the past 18 months.

Manufacturers stress that **economic viability still needs to be demonstrated**, and is crucial to the success of this strategy. A few success factors should be considered, such as:

- **Large-scale facilities** need to be prioritised
- Manufacturers should be able to export their products to the **continental market**
- A mechanism will be needed to **subsidise locally manufactured vaccines**

African manufacturers identify **three major risks** to the desired economic viability:

- **Sustainability risk**: lack of concrete measures, uncoordinated effort
- **Strategic risk**: broad strategy, need for further prioritisation to guide manufacturers’ efforts and investments in the short- and mid-term
- **Support risk**: concern about loss of attention and effort over time as the Covid-19 pandemic recedes
There are several prerequisites to creating conditions for a sustainable ecosystem for African vaccine manufacturers:

- **Advance purchase agreements** from African governments
- **A review of the procurement mechanisms**
- **Financial mechanisms** to counterbalance the lack of price-competitiveness
- **Coordination mechanisms** to improve information sharing

African manufacturers should focus on **strategic and realistic priorities** to initiate change. They need to prioritise supply-constrained products with less complex end-to-end manufacturing processes in the short- and mid-term.

**Donors must provide manufacturers with sufficient and sustained support.** Access to finance, Talent and Technology transfers emerged as their most pressing challenges beyond the market-access prerequisites - selection of potential initiatives identified by manufacturers:

1. **Access to finance:** Offer tailored and low-cost funding with longer payback periods for manufacturing facility investment projects
2. **Talent:** Support manufacturers to gain practical experience by funding secondments with experienced manufacturers and by bringing global experts on local sites
3. **Technology transfers:** Collaborate with African manufacturers and partners on technology transfer to support capacity building, before they can attract potential private partnerships.

There is an important for global health stakeholders to recognise the economic and operational reality of the African manufacturers, who have such a crucial role in attaining the public-health objectives. The mood among stakeholders is one of optimism - that the current and forthcoming efforts will succeed in scaling up Africa’s vaccine-manufacturing capacity.